Sanofi scraps development of amcenestrant breast cancer treatment

PARIS — French healthcare company Sanofi said it would end the development program of amcenestrant, an estrogen receptor degrader aimed at treating breast cancer. The move puts more pressure on Sanofi to revive its drug development success rate, after it fell far behind in the race to develop COVID-19 vaccines. “This was a flagship drug […]